Project Grant R01AR085028
Award Date
6/1/25
Completion Date
5/31/30
Dollars Obligated
$530K
Similar Awards
This federal Project Grant award of $170,101 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research to characterize the spatial heterogeneity of synovial inflammation in rheumatoid arthritis (RA). The principal investigator at Brigham & Women's Hospital Inc. will use advanced statistical techniques and artificial intelligence to identify the spatial...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $139,895 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to Brigham & Women's Hospital Inc. in Boston, MA. The grant aims to investigate the role of "trained immunity" in linking inflammatory arthritis to the development of cardiovascular disease. Specifically, the research will test the hypothesis that inflammatory responses in...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research into the role of the INPP5E signaling pathway in the pathogenesis of rheumatoid arthritis (RA). The $553,248 award, effective July 18, 2024 through June 30, 2029, aims to: Investigate whether deletion or overexpression of INPP5E in macrophages significantly alters inflammation...
This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $735,372 to Brigham & Women's Hospital Inc. to conduct research on T cell expression of inflammatory chemokine receptors in chronic autoimmune conditions. The research aims to identify transcription factors and cytokines that regulate the expression of key chemokine receptors,...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to advance the development of a novel oral, first-in-class therapeutic for the treatment of rheumatoid arthritis (RA). The project aims to conduct pharmacokinetic and safety studies, characterize the effects of the lead compound on human fibroblast-like...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $402,086 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Utah to develop a joint-targeted antibody therapy for treating rheumatoid arthritis (RA). The research aims to localize anti-inflammatory antibody drugs to arthritic joints using a collagen-hybridizing peptide that can bind to degraded collagen in joint tissue undergoing...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $506,085 to the University of California, San Diego (UC San Diego) to investigate the use of obesity-induced inflammatory mediators as predictive biomarkers for response to biological therapies in patients with rheumatoid arthritis (RA). The 5-year project, effective September 1,...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $628,174 to the University of Southern California to conduct research on the cellular origins and molecular mechanisms of arthrofibrosis. The study aims to investigate the role of arginine metabolism and GP130 signaling pathways in promoting fibrotic responses within the joint after injury,...
This $570,878 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research into modulating myofibroblast dynamics to enhance tendon healing following injury. The research aims to define the efficacy of pharmacologically activating the GPR68 receptor to regulate the transition between tenocytes and myofibroblasts during fibrotic tendon healing....